Sanofi (SNY) Tops Q3 EPS by 117c; offers Outlook

Sanofi (NASDAQ: SNY) reported Q3 EPS of EUR2.55, EUR1.17 better than the analyst estimate of EUR1.38. Revenue for the quarter came in at EUR11.96 billion versus the consensus estimate of EUR13.2 billion.

OUTLOOK

Full-year 2023 business EPS guidance reiterated

Sanofi expects 2023 business EPS(1) to grow mid single-digit(2) at CER, barring unforeseen major adverse events. Applying average October 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -6.0% to -7.0%. This guidance includes approximately €400 million of expected one-off COVID vaccine revenues in the fourth quarter.

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• AeroVironment restates quarterly financials, citing $89M goodwill error
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight